In paroxysmal nocturnal hemoglobinuria (PNH), little is known about the molecular events leading to the clinical manifestations except for the hemolysis. To unfold the complex pathophysiology, it is necessary to elucidate the nature of the PNH clone. PNH exhibits an acquired stem cell disorder, a clonal expansion of affected cells, concomitant depression of normal hematopoiesis in bone marrow (BM), and, although infrequently, the development of leukemia. The PNH clone is thus expected to exhibit some neoplastic features. We report here that CD34+ hematopoietic progenitor cells of PNH-BM yielded blood cells of three lineages with AROXYSMAL nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder of a clonal nature that is characterized by various clinical manifestations such as intravascular hemolysis, frequent episodes of infection, thrombosis, bone marrow (BM) hypoplasia, and infrequent development of leukemia."' The hemolysis is attributable to the enhanced susceptibility of erythrocytes to autologous complement.'.* The abnormal sensitivity is explained by a lack of the complement regulatory membrane proteins such as decay-accelerating factor (DAF) and CD59 that are covalently linked to the erythrocyte membrane through a glycosylphosphatidylinositol (GPI) anchor.".' The deficiency of the membrane proteins is caused by a synthetic defect of the anchor due to the impaired transfer of N-acetylglucosamine to phosphatidylinositol.6-'o A gene responsible for the anchor defect was also cloned and is named P G A . ".'* The molecular nature of membrane disorders that cause abnormal sensitivity to complement has thus been disclosed. Moreover, a possible mechanism of intravascular activation of complement has also been proposed in an infection-associated hemolytic precipitation.'' Thus, the entire mechanism of the hemolysis characteristic of PNH is now being rapidly clarfied. However, except for the hemolysis, the molecular events leading to the clinical manifestations (including BM hypoplasia and thrombosis, which are major causes of death in PNH) are not yet clear. 
PNH phenotype alone when transplanted into sublethally irradiated severe combined immunedeficient mice. The hematopoiesis persisted for more than 10 months and did not always need human cytokines. In contrast, the hematopoiesis by control grafts obtained from healthy volunteers required an intense cytokine treatment. This in vivo model defines the preferential hematopoiesis of pluripotent PNH progenitor cells, indicating the intrinsic growth abnormality of PNH clone.
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complex pathophysiology of PNH, the nature of PNH clone needs to be uncovered. It is well known that PNH shows a considerable expansion of affected clone despite its complement susceptibility."'"'~ For the clonal expansion, two possibilities are raised: a growth and a survival advantage of affected clone in vivo.I5 Recent reports support the latter rather than the former possibility.''.'h However, considering that PNH is an acquired stem cell disorder with depression of BM hematopoiesis and leukemic conver~ion,l-~.'~ we expected that PNH clone harbors some neoplastic features comprising a growth abnormality. Accordingly, we characterized the growth property of PNH clone in vivo by the analysis of hematopoietic reconstitution with CD34+ PNH cells transplanted into sublethally irradiated severe combined immunedeficient (SCID) mice that are often used for in vivo stem cell
MATERIALS AND METHODS
BM transplantation. BM cells were obtained after consent from 7 patients with PNH and 5 healthy volunteers. Fresh cells of heparinized BM aspirate were centrifuged with Ficoll-Hypaque to collect immature mononuclear cell^.^" Cells suspended in RPM1 1640 medium were left in plastic tissue-culture plates to allow such cells as stromal cells and macrophages to adhere. Nonadherent cells were incubated with magnetizable polystyrene beads coated with monoclonal antibody (MoAb) against CD2 and CD19 (Dynal, Oslo, Norway) to remove both T and B lymphocytes and other cells adherent to the beads.*" From the lymphocyte-depleted immature cell fraction, hematopoietic progenitor cells were enriched by incubation with beads coated with mouse MoAb to CD34 (a marker of hematopoietic stem cells; Dynal)." An aliquot of the progenitors was used for flow cytometric analysis, and the remainder was injected into the tail veins of nonleaky S-week-old female SCID mice ( IO' to 5 X l O5 cells/200 pL saline/mouse) 1 day after sublethal 400 cGy irradiation. The mice were then treated intraperitoneally three times per week with human interleukin-3 (IL-3; 400 nghouse; Sandoz, Basel, Switzerland) and human stem cell factor (SCF; 5 pg/mouse; Amgen, Thousand Oaks, CA).
Flow cytornetry.. To evaluate the hematopoietic reconstitution, the cells in the BM, the spleen, and the peripheral blood (PB) of the mice were analyzed 3 (or S), 7 , and 10 months after transplantation by two-color flow cytometry with MoAb to GPI-anchored membrane proteins and with MoAb to distinctive lineage-specific surface markers of human blood cells, as described previously.","',2' Fluores- 
IO5
in 100 pL phosphate-buffered saline [PBS]) were spun down to a microslide glass with a centrifuge (Cytospin 2; Shandon Southern Products, Cheshire, UK), fixed with 1% paraformaldehydelPBS for 10 minutes at room temperature, washed three times with PBS, and incubated with FITC-conjugated MoAb to human CD45 and CD59 for 60 minutes. After being washed with PBS, the cells were viewed in 10% nonfluorescein glycerin/PBS using an Olympus microscope equipped with epifluorescence optics (BX60) and photographed under 250 X original magnification with Sensia 100 Fuji-film (Fuji Photo Film CO, Tokyo, Japan).
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of human PIG-A transcripts. Total RNA (30 to 50 pg) was isolated from IO' human leukocytes and mouse spleen cells. After initial denaturation at 65°C for 5 minutes, RNA (2 pg) was subjected to reverse transcription, as described elsewhere," using a primer (5'-AATGATATAGAGGTAGCATAAC-3') for human PIG-A and a primer (5'-AACCATACAGAGGTAGCAAATC-3') for murine Pig- agarose-gel electrophoresis and analyzed by autoradiography.
RESULTS AND DISCUSSION
BM cells enriched with CD34+ cells are considered to hold pluripotent hematopoietic progenitor cells efficient for in vivo stem cell assay with SCID m i~e . '~. ' * .~~ In the control BM grafts obtained from 5 healthy volunteers and the BM grafts obtained from 7 patients with PNH, the population of CD34+ cells exceeded 90% and ranged from 60% to 87%, respectively (Table 1) . Despite showing a chimera of normal and PNH clones, most of the CD34+ cells in the PNH grafts exhibited the PNH phenotype, ie, lack of GPI-anchored membrane proteins CD59 and DAF,20,22 whereas the control grafts consisted of normal clones alone ( Table 1) . Up to 5 months after BM transplantation, human blood cells were detected in none of the 12 SCID mice (7 with PNH grafts and 5 with control grafts obtained from individual donors). Seven months after transplantation, human blood cells were still nondetectable in all of another 5 mice receiving transplants of control grafts that contained markedly more CD34+ cells than the PNH grafts (Table 1 ). In contrast, human blood cells were detectable in the BM and the spleen of all 10 mice receiving transplants of PNH grafts from 7 donors (SCID-hu/PNH; Table 1); they were detected by both flow cytometry and indirect immunofluorescence staining with MoAb that reacted selectively with human cells (data not shown). However, human cells were not detected in the PB of these mice by these analyses. Human cells in the mice were further identified by detection of the transcripts of the human PIG-A gene (Fig lA, lanes 6 , 8 , and 10 ) by RT-PCR with primers specific to the human PIG-A sequence (Fig lA,  lanes 1 through 5, and Fig 1B) Table 1 ). respectively. (B1 Species specificity of the primers used for RT-PCR. Lane 1, products of normal human leukocytes using primers for human PIG-A; lanes 2 and 3, products of SClD mouse spleen cells and normal human leukocytes, respectively, using primers for the murine homologue Piga.2' IC) Analysis with primers for human PIG-A in the spleen cells of SCID-hulcontrol (lanes 1 through 3) and SCID-hu/PNH (lanes 4 through 6) mice. The mice received grafts from individual donors. Cytokine treatment: lane 1, moderately as described in the Materials and Methods; lanes 2 and 3, intensely with IL-3 (2 pg), SCF (10 pg), and granulocyte-macrophage colony-stimulating factor (GM-CSF; 2 pg; Amgen, Thousand Oaks, CAI every other day; lanes 4 through 6, no cytokines.
further confirmed by Southern blot analysis with a full-length PIG-A cDNA probe (data not shown). In the mouse showing the most fruitful results, the percentages of BM cells positive for human blood cell markers were 26% for CD7 I , 7% for glycophorin, 9% for CD13, 15% for CD33, 24% for CD45, 9% for CD19, 3% for CD2, and 0% for CD34 ( Table 1 ) . These populations seem to be comparable to or higher than the populations of human cells identified in current in vivo stem cell assays with SCID The second experiment with PNH grafts from 2 of the 7 donors shown in Table  1 showed that PNH hematopoiesis persisted for more than IO months after transplantation (data not shown). In the SCID-hu/PNH mice that survived for more than 7 months after transplantation, the appearance of the human erythroid, myeloid. and lymphoid cells suggests that they originated from human pluripotent hematopoietic progenitor cells. The population of pluripotent progenitors in CD34' BM cells appears to be at most l%'R~27.2X; thus, it is possible that the differences in the populations of human cells among the in vivo assays (Table 1) primarily reflect the content of each graft, in terms of the number and growth properties of the progenitors. Although the PNH grafts contained a low population (from 7% to 19%) of cells with a normal phenotype (Table I) , virtually all of the human blood cells detected in the mice showed a PNH phenotype (data not shown). It is also notable that the PNH grafts carrying more than 5 X IO' of affected CD34' cells yielded human cells with varying populations from less than 2% to 41% (Table l) , whereas human cells were detected in none of the 7 mice receiving transplants of PNH grafts carrying less than IO' of affected CD34' cells. Human cells were not detected in the SCID mice treated only with cytokines that had not undergone BM transplantation. Thus. our multiple in vivo assays explicitly showed the hematopoietic advantage of the PNH clone over normal clones.
The preferential hematopoiesis exhibited by PNH clone in the assays can be attributed, in general, to an advantage of engraftment, cell growth, and survival in vivo. Intense stimulation with human cytokines induced a genetically detectable hematopoiesis by normal clones of control grafts 7 months after transplantation (SCID-hdcontrol: Fig IC. lanes  2 and 3) . Normal progenitors might be in a latent state incapable of obvious hematopoiesis in the absence or insufficiency of cytokines." It thus seems to be difficult to confirm the difference in engraftment efficiency between the PNH and control clones. In contrast, human cells were barely For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From detectable in the mice transplanted with PNH grafts despite the absence of cytokine treatment (Fig lC, lanes 4 through  6) . Namely, the PNH clone exhibited cytokine-independent hematopoiesis. These findings suggest the existence of an intrinsic growth abnormality in the PNH clone. This abnormality is supported by previous reports of a poor proliferative response to IL-2 of PNH T cells compared with control T cells in and the retarded hematopoiesis by the PNH clone in the BM of patients with PNH." The growth property of the PNH clone thus appears to be a slow but steady proliferation. The lack of detection of mature human cells in the PB of SCID-hu/PNH mice may imply the requirement of further factors, such as erythropoietin and granulcoyte colony-stimulating factor for the terminal differentiation of the PNH clone." For the preferential hematopoiesis by PNH clone in the SCID mice, whose immune system is impaired genetically3' and was further damaged by sublethal irradiation in the present study, a growth advantage brought about by an endogenous growth abnormality of PNH clone appears more conceivable than a survival advantage by escape from immunologic clearan~e.'~,'~ Certainly, the possibility is not excluded that PNH clone exhibits both a survival and a growth advantage over normal clones. Of interest is whether the growth abnormality is attributable to PIG-A mutation, which is responsible for the GPI-anchor defect characteristic of PNH cell^.^.'^ Identification of the molecular mechanism of this abnormality would shed some light on the complex pathophysiology of PNH. This in vivo model could also be useful for future investigations of PNH. 29. Nakakuma H, Nagakura S, Horikawa K, Hidaka M, Kawaguchi T, Iwamoto N, Sanada I, Kagimoto T, Takatsuki K: Interleukin-2-dependent T-cell lines established from paroxysmal nocturnal hemoglobinuria patients. Blood 84: 309, 1994 30. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 301527, 1983 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
